Dew this is for the idix followers from bloomberg news..
Gilead's Hepsera Doesn't Always Work as Hepatitis B Backstop April 26, 2006 17:58 EDT -- Gilead Sciences Inc.'s Hepsera for hepatitis B isn't universally effective for patients who develop resistance to other treatments, according to a study that says testing and better drugs are needed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.